Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy

Claudio Ponticelli, Pietro Zucchelli, Patrizia Passerini, Bruno Cesana, P. Altieri, P. Melis, C. Pozzi, F. Locatelli, P. Zucchelli, S. Pasquali, A. Salvadeo, M. Sasdelli, B. Redaelli, A. Lupo, G. Maschio, C. Grassi, R. Bellazzi, R. Scanziani, M. Fusaroli, G. MeccaC. Ponticelli, P. Passerini, G. Banfi

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Background and Methods. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). Results. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). Conclusions. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.

Original languageEnglish
Pages (from-to)599-603
Number of pages5
JournalNew England Journal of Medicine
Volume327
Issue number9
Publication statusPublished - Aug 27 1992

Fingerprint

Chlorambucil
Membranous Glomerulonephritis
Methylprednisolone
Nephrotic Syndrome
Therapeutics
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ponticelli, C., Zucchelli, P., Passerini, P., Cesana, B., Altieri, P., Melis, P., ... Banfi, G. (1992). Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. New England Journal of Medicine, 327(9), 599-603.

Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. / Ponticelli, Claudio; Zucchelli, Pietro; Passerini, Patrizia; Cesana, Bruno; Altieri, P.; Melis, P.; Pozzi, C.; Locatelli, F.; Zucchelli, P.; Pasquali, S.; Salvadeo, A.; Sasdelli, M.; Redaelli, B.; Lupo, A.; Maschio, G.; Grassi, C.; Bellazzi, R.; Scanziani, R.; Fusaroli, M.; Mecca, G.; Ponticelli, C.; Passerini, P.; Banfi, G.

In: New England Journal of Medicine, Vol. 327, No. 9, 27.08.1992, p. 599-603.

Research output: Contribution to journalArticle

Ponticelli, C, Zucchelli, P, Passerini, P, Cesana, B, Altieri, P, Melis, P, Pozzi, C, Locatelli, F, Zucchelli, P, Pasquali, S, Salvadeo, A, Sasdelli, M, Redaelli, B, Lupo, A, Maschio, G, Grassi, C, Bellazzi, R, Scanziani, R, Fusaroli, M, Mecca, G, Ponticelli, C, Passerini, P & Banfi, G 1992, 'Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy', New England Journal of Medicine, vol. 327, no. 9, pp. 599-603.
Ponticelli, Claudio ; Zucchelli, Pietro ; Passerini, Patrizia ; Cesana, Bruno ; Altieri, P. ; Melis, P. ; Pozzi, C. ; Locatelli, F. ; Zucchelli, P. ; Pasquali, S. ; Salvadeo, A. ; Sasdelli, M. ; Redaelli, B. ; Lupo, A. ; Maschio, G. ; Grassi, C. ; Bellazzi, R. ; Scanziani, R. ; Fusaroli, M. ; Mecca, G. ; Ponticelli, C. ; Passerini, P. ; Banfi, G. / Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. In: New England Journal of Medicine. 1992 ; Vol. 327, No. 9. pp. 599-603.
@article{6e43cc1067a24818801a356e83415747,
title = "Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy",
abstract = "Background and Methods. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). Results. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). Conclusions. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.",
author = "Claudio Ponticelli and Pietro Zucchelli and Patrizia Passerini and Bruno Cesana and P. Altieri and P. Melis and C. Pozzi and F. Locatelli and P. Zucchelli and S. Pasquali and A. Salvadeo and M. Sasdelli and B. Redaelli and A. Lupo and G. Maschio and C. Grassi and R. Bellazzi and R. Scanziani and M. Fusaroli and G. Mecca and C. Ponticelli and P. Passerini and G. Banfi",
year = "1992",
month = "8",
day = "27",
language = "English",
volume = "327",
pages = "599--603",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy

AU - Ponticelli, Claudio

AU - Zucchelli, Pietro

AU - Passerini, Patrizia

AU - Cesana, Bruno

AU - Altieri, P.

AU - Melis, P.

AU - Pozzi, C.

AU - Locatelli, F.

AU - Zucchelli, P.

AU - Pasquali, S.

AU - Salvadeo, A.

AU - Sasdelli, M.

AU - Redaelli, B.

AU - Lupo, A.

AU - Maschio, G.

AU - Grassi, C.

AU - Bellazzi, R.

AU - Scanziani, R.

AU - Fusaroli, M.

AU - Mecca, G.

AU - Ponticelli, C.

AU - Passerini, P.

AU - Banfi, G.

PY - 1992/8/27

Y1 - 1992/8/27

N2 - Background and Methods. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). Results. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). Conclusions. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.

AB - Background and Methods. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). Results. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). Conclusions. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.

UR - http://www.scopus.com/inward/record.url?scp=0026687712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026687712&partnerID=8YFLogxK

M3 - Article

C2 - 1640953

AN - SCOPUS:0026687712

VL - 327

SP - 599

EP - 603

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -